1. Division of Clinical Pharmacology (M.L., L.W., R.M.W.), Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905;
2. Massachusetts General Hospital (P.E.G.), Harvard University, Boston, Massachusetts 02114;
3. Departments of Oncology (J.N.I.), Mayo Clinic, Rochester, Minnesota 55905;
4. Rikagaku Kenkyūsho Center for Integrative Medical Science (M.K., Y.F.), Yokohama, Japan 230-0045;
5. Health Sciences Research (A.B., G.D.J., E.E.C., D.J.S.), Mayo Clinic, Rochester, Minnesota 55905;
6. School of Medicine (Y.N.), Chicago University, Chicago, Illinois 60637;
7. National Cancer Institute of Canada Clinical Trials Group (J.-A.W.C., L.E.S.), Kingston, Ontario, Canada K7L 3N6;
8. Division of Oncology (M.J.E.), Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110
9. Division of Endocrinology (S.K.), Mayo Clinic, Rochester, Minnesota 55905;